VB119 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 222 | Primary nephrotic syndrome | 1 |
222. Primary nephrotic syndrome
Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04652570 (ClinicalTrials.gov) | May 5, 2021 | 23/11/2020 | Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy | A Phase 1b/2a Study of VB119 in Adult Subjects With Primary Membranous Nephropathy | Membranous Nephropathy | Drug: VB119 | ValenzaBio, Inc. | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 1/Phase 2 | United States;United Kingdom |